NCT01518894View on ClinicalTrials.gov

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

PF-04958242

PF-04958242 0.10 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.20 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)

DRUG

Placebo

Placebo oral solution Q24 hours for 14 days

Trial Locations (1)

90806

Pfizer Investigational Site, Long Beach

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY